Evolution of the Average Target: Edwards Lifesciences Corporation

Evolution of the Average Target - Edwards Lifesciences Corporation

Evolution of the Target Price: Edwards Lifesciences Corporation

Evolution of the Target Price - Edwards Lifesciences Corporation

Changes in Analyst Recommendations: Edwards Lifesciences Corporation

74ca4655074adddd0d.MSDyDE3LUKsHYAnDOebK5aOtYCtFQY6MHaxQosSkbrM.e0mqXiijGcZOVzy3W468ivTZUkkUBeG1eNUG7Z2QCsdHUsdhCJsEz20Cbg~fd77cdb394cb098b8915f6b39d01aa21
11:52am Edwards Lifesciences' Progress Data Unlikely to Expand TAVR Market, RBC Says MT
10-15 Baird Adjusts Price Target on Edwards Lifesciences to $90 From $94 MT
10-05 Evercore ISI Adjusts Price Target on Edwards Lifesciences to $102 From $100, Keeps Outperform Rating MT
10-02 JPMorgan Adjusts Price Target on Edwards Lifesciences to $105 From $100, Keeps Overweight Rating MT
09-30 Edwards Lifesciences' TAVR Evaluation in Moderate Aortic Stenosis Among Most Awaited Clinical Trial Readouts, Oppenheimer Says MT
08-21 Argus Adjusts Price Target on Edwards Lifesciences to $115 From $105, Maintains Buy Rating MT
07-28 UBS Upgrades Edwards Lifesciences to Buy From Neutral, Adjusts Price Target to $110 From $90 MT
07-27 Rothschild & Co Redburn Adjusts Edwards Lifesciences Price Target to $102 From $99, Maintains Buy Rating MT
07-24 Edwards Lifesciences Seen Building on Catalyst Pipeline, RBC Says MT
07-24 Deutsche Bank Adjusts Edwards Lifesciences Price Target to $103 From $100, Maintains Buy Rating MT
07-24 Raymond James Adjusts Price Target on Edwards Lifesciences to $103 From $100, Maintains Outperform Rating MT
07-24 Piper Sandler Adjusts Price Target on Edwards Lifesciences to $101 From $100, Maintains Overweight Rating MT
07-24 Jefferies Adjusts Price Target on Edwards Lifesciences to $105 From $102, Maintains Buy Rating MT
07-24 Bernstein Adjusts Price Target on Edwards Lifesciences to $99 From $96, Maintains Market Perform Rating MT
07-24 Leerink Partners Upgrades Edwards Lifesciences to Outperform From Market Perform, Adjusts PT to $101 From $87 MT
07-16 Truist Adjusts Price Target on Edwards Lifesciences to $95 From $90, Maintains Hold Rating MT
07-15 Mizuho Adjusts Price Target on Edwards Lifesciences to $105 From $100, Maintains Outperform Rating MT
07-14 Baird Adjusts Price Target on Edwards Lifesciences to $94 From $87, Maintains Neutral Rating MT
07-14 Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $102 From $98, Maintains Buy Rating MT
07-13 RBC Raises Price Target on Edwards Lifesciences to $110 From $100, Keeps Outperform Rating MT
07-08 Citigroup Adjusts Edwards Lifesciences Price Target to $110 From $101 MT
07-06 Evercore ISI Adjusts Price Target on Edwards Lifesciences to $100 From $93 MT
06-30 BTIG Adjusts Price Target on Edwards Lifesciences to $110 From $100, Maintains Buy Rating MT
06-29 Edwards Lifesciences Can Sustain Strong Revenue Growth on Technological Leadership, RBC Says MT
06-16 Edwards Lifesciences Seen Benefiting From CMS Transcatheter Aortic Valve Replacement Rule, RBC Says MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+9.23%
+10.18%
+14.01%
+10.48%
+11.91%
+4.6%
-1.13%
+5.85%
+3.63%
+15.46%
Average +8.42%
Weighted average by Cap. +9.67%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
93.26USD
Average target price
101.87USD
Spread / Average Target
+9.23%
High Price Target
117.00USD
Spread / Highest target
+25.46%
Low Price Target
84.00USD
Spread / Lowest Target
-9.93%

Analyst Consensus Detail

Analyst consensus - Edwards Lifesciences Corporation

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Edwards Lifesciences Corporation
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Edwards Lifesciences Corporation
  1. Stock Market
  2. Stocks
  3. EW Stock
  4. Consensus Edwards Lifesciences Corporation